Premium
Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma
Author(s) -
Siehl Jan M.,
Thiel Eckhard,
Schmittel Alexander,
Hütter Gero,
Deckert Peter M.,
Szelényi Hubert,
Keilholz Ulrich
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21211
Subject(s) - ifosfamide , medicine , regimen , chemotherapy , surgery , tolerability , soft tissue sarcoma , chemotherapy regimen , anthracycline , sarcoma , oncology , cancer , soft tissue , adverse effect , breast cancer , etoposide , pathology
BACKGROUND The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma. To improve the tolerability and potential efficacy of this combination, the authors combined a moderate dose of continuous infusion ifosfamide with liposomal daunorubicin (L‐Dauno). METHODS In a single‐arm, Phase II study, 40 patients with a median age of 57 years (range, 19–78 years) were enrolled. Of these, 35 patients were treated with first‐line chemotherapy. The treatment regimen was comprised of ifosfamide at a dose of 5 g/m 2 over 24 hours and L‐Dauno at a dose of 100 mg/m 2 every 4 weeks with granulocyte–colony‐stimulating factor support. RESULTS Eleven (31%) of 35 anthracycline/ifosfamide‐naive patients achieved a partial/complete response, 6 patients (17%) had stable disease, and 13 patients (37%) had disease progression. Three patients were not evaluable, and there were two intermittent deaths. The median time to disease progression was 6 months, the median overall survival was 14 months, and the median time to treatment failure was 15 months. Toxicity was tolerable. CONCLUSIONS The combination of Ifosfamide and L‐Dauno was found to be a highly active chemotherapy regimen for first‐line treatment of soft tissue sarcoma. Therefore, we believe randomized studies with this regimen are warranted. Cancer 2005. © 2005 American Cancer Society.